Followers | 3170 |
Posts | 208744 |
Boards Moderated | 2 |
Alias Born | 02/04/2004 |
Tuesday, June 28, 2022 8:14:49 AM
Virginia A. Schad, PharmD, RPh
May 5, 2022
Doctor examining patients lungs, back, chest exam
Morphological analysis of lung tissue can offers insight into pathogenic mechanisms of post-COVID pulmonary sequelae and thereby guide clinical management.
Post-COVID lung disease includes 3 different subtypes or subgroups that potentially require separate and different management, according to a study published in the European Respiratory Journal.
Consequences of prolonged multi-organ symptoms and complications from COVID-19 infection are a growing health concern. Residual organ damage post-COVID-19 range from self-limited abnormalities to major lung diseases. Histological evaluation of lung tissue may reveal peculiar morpho-phenotypical changes which may help aid clinicians in understanding of pathogenic mechanisms and in providing appropriate therapy, the researchers noted.
In the current study, researchers examined the morphologic and immuno-molecular features of transbronchial lung cryobiopsies performed in patients with persistent lung disease after recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. From January through March 2021, investigators conducted a comparative, prospective, observational study of adult patients referred to multiple centers for suspected pulmonary sequelae after COVID-19. All patients had recovered from COVID-19-related pneumonia at least 30 days prior, although none had been intubated, and had persistent lung involvement on high-resolution computed tomography scans and persistent respiratory and/or systemic symptoms. Most patients reported fatigue and low grade fever, with some reporting joint and muscle pain and depression.
Of the 164 referred patients, investigators conducted extensive analysis of 10 patients with parenchymal lung disease (extent >5%) who underwent lung biopsy. The researchers found that the histological pattern was not homogeneous among the patients; they noted 3 different “case clusters” characterized by specific clinical and radiological features. Cluster 1 (“chronic fibrosing”; n=2) was characterized by post-infection progression of pre-existing interstitial pneumonias, cluster 2 (“acute/subacute injury”; n=5) was characterized by different types and grades of lung injury ranging from organizing pneumonia and fibrosing nonspecific interstitial pneumonia to diffuse alveolar damage, and cluster 3 (“vascular changes”; n=3) was characterized by diffuse vascular increase, dilatation, and distortion of capillaries and venules within otherwise normal parenchyma. In particular, clusters 2 and 3 were characterized by immunophenotypical changes similar to those observed in early/mild COVID-19 pneumonias.
To date, this study appears to be the first correlating histological/immunohistochemical patterns with clinical and radiological pictures of patients with post-COVID lung disease. The researchers concluded that a multidisciplinary evaluation of patients with suspected long-COVID lung disease is needed to potentially characterize their phenotype and thereby provide insight into the most appropriate therapeutic interventions for managing a given patient.
This study was limited by its small sample size, short time frame, and the lack of baseline pulmonary patient data.
Reference
Ravaglia C, Doglioni C, Chilosi M, et al. Clinical, radiological, and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection. Eur Respir J. Published online March 17, 2022. doi:10.1183/13993003.02411-2021
https://www.pulmonologyadvisor.com/home/topics/lung-infection/long-covid-lung-disease-phenotypes/
Recent TSOI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:44:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:44:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 06:14:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 07:42:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 07:38:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:44:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:39:55 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:51:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 04:47:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:46:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:44:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/30/2024 06:46:26 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 04:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 10:03:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM